Idaho Healthcare Hub
SEE OTHER BRANDS

Following health and wellness news from Idaho

Idaho Healthcare Hub: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Idaho Healthcare Hub.

Press releases published on May 27, 2025

dacadoo Launches Generation 5 of Its Award-Winning Digital Health Engagement Platform

dacadoo Launches Generation 5 of Its Award-Winning Digital Health Engagement Platform

Zurich, CH, May 27, 2025 (GLOBE NEWSWIRE) -- dacadoo, a global leader in digital health engagement technology since 2010 with over 100 granted patents, announces the launch of Generation 5 of its Digital Health EngagementPlatform (DHEP). This next- …

Salvia BioElectronics Secures $60M in Oversubscribed Series B  to Bring its Pioneering Migraine Therapy to Market

Salvia BioElectronics Secures $60M in Oversubscribed Series B to Bring its Pioneering Migraine Therapy to Market

Series B funding round led by Innovation Industries, with participation from Invest-NL, EIC Fund, and existing investors Inkef, Panakès Partners, SHS Capital, Dolby Family  Ventures, Brabant Development Agency (BOM) and Thuja Capital. Proceeds will fund …

Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan

Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan

Exclusive Japanese partner Kowa has received regulatory approval to initiate Phase 3 clinical trials on NCX 470 for the treatment of ocular hypertension in Japan Milestone payments from Kowa totaling €3 million expected to be received by Nicox in 2025 …

Nicox annonce jusqu’à 3 millions d’euros de paiements d’étapes de la part de Kowa en 2025, alors que NCX 470 se prépare à entrer en essais cliniques de Phase 3 au Japon

Nicox annonce jusqu’à 3 millions d’euros de paiements d’étapes de la part de Kowa en 2025, alors que NCX 470 se prépare à entrer en essais cliniques de Phase 3 au Japon

27 mai 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui que son partenaire exclusif au Japon pour NCX …

Augustine Therapeutics announces first patient dosed in Phase I clinical trial evaluating lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth disease

Augustine Therapeutics announces first patient dosed in Phase I clinical trial evaluating lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth disease

AGT-100216 is the first HDAC6 inhibitor from Augustine’s pipeline to enter clinical trials LEUVEN, Belgium – 27 May 2025– Augustine Therapeutics NV (“Augustine” or “the Company”), a biotechnology company focused on developing new therapies for …

Press Release: Sanofi completes acquisition of DR-0201

Press Release: Sanofi completes acquisition of DR-0201

Sanofi completes acquisition of DR-0201 Paris, May 27, 2025. Sanofi announces the completion of its acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private clinical-stage biopharmaceutical company. The acquisition …

Communiqué de presse : Sanofi finalise l’acquisition du DR-0201

Communiqué de presse : Sanofi finalise l’acquisition du DR-0201

Sanofi finalise l’acquisition du DR-0201 Paris, le 27 mars 2025. Sanofi annonce la finalisation de l’acquisition du DR-0201, un anticorps bispécifique ciblé qui engage les cellules myéloïdes, à Dren Bio, Inc., société biopharmaceutique privée au stade …

Press release: Sequana Medical Secures Additional Convertible Financing of EUR 6.3 Million from SFPIM and Other Existing Shareholders

Press release: Sequana Medical Secures Additional Convertible Financing of EUR 6.3 Million from SFPIM and Other Existing Shareholders

Sequana Medical Secures Additional Convertible Financing of EUR 6.3 Million from SFPIM and Other Existing Shareholders Continued strong support from major shareholders  alfapump® US commercial launch remains on track for Q3 2025 through specialty …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service